Hikma Pharmaceuticals (HIK) Stock Rating Reaffirmed by Numis Securities

Hikma Pharmaceuticals (LON:HIK)‘s stock had its “buy” rating reissued by analysts at Numis Securities in a research note issued on Wednesday. They presently have a GBX 1,300 ($17.50) target price on the stock. Numis Securities’ target price suggests a potential upside of 13.84% from the company’s current price.

Several other equities analysts also recently commented on HIK. Jefferies Group upped their target price on Hikma Pharmaceuticals from GBX 1,045 ($14.06) to GBX 1,074 ($14.45) and gave the company a “hold” rating in a research report on Monday, December 4th. Morgan Stanley reaffirmed an “equal weight” rating and issued a GBX 1,100 ($14.80) target price on shares of Hikma Pharmaceuticals in a research report on Friday, December 1st. Peel Hunt reaffirmed a “hold” rating and issued a GBX 1,390 ($18.71) target price on shares of Hikma Pharmaceuticals in a research report on Wednesday, November 15th. J P Morgan Chase & Co decreased their target price on Hikma Pharmaceuticals from GBX 1,250 ($16.82) to GBX 1,000 ($13.46) and set a “neutral” rating on the stock in a research report on Friday, November 10th. Finally, decreased their target price on Hikma Pharmaceuticals from GBX 1,060 ($14.27) to GBX 865 ($11.64) and set a “reduce” rating on the stock in a research report on Friday, November 10th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and two have assigned a buy rating to the company. The company has an average rating of “Hold” and an average target price of GBX 1,188.90 ($16.00).

Shares of Hikma Pharmaceuticals (LON:HIK) opened at GBX 1,142 ($15.37) on Wednesday. Hikma Pharmaceuticals has a 52 week low of GBX 906.50 ($12.20) and a 52 week high of GBX 2,346 ($31.57).

TRADEMARK VIOLATION WARNING: “Hikma Pharmaceuticals (HIK) Stock Rating Reaffirmed by Numis Securities” was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be accessed at https://www.com-unik.info/2017/12/22/hikma-pharmaceuticals-hik-stock-rating-reaffirmed-by-numis-securities.html.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.

Analyst Recommendations for Hikma Pharmaceuticals (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit